Potential interaction of troglitazone and cyclosporine

Bruce Kaplan, Gary Friedman, Martin Jacobs, Ronald Viscuso, Neil Lyman, Penny DeFranco, Luigi Bonomini, Shamkant P. Mulgaonkar

    Research output: Contribution to journalArticlepeer-review

    31 Scopus citations


    Background: Troglitazone (Rezulin) is a promising new oral hypoglycemic agent recently approved by the Federal Drug Administration for use in type II diabetes mellitus. Although troglitazone is not metabolized by the cytochrome p450 3A isozyme family, it is a potential inducer of this system. Other medications, e.g., rifampin and phenobarbital, which also induce p450 3A activity, have been reported to significantly decrease cyclosporine (CsA) concentrations. Methods. We report a case of a stable renal transplant patient who had a decrease in CsA concentration after beginning troglitazone and who subsequently developed an acute rejection episode. We then reviewed all stable renal patients begun on troglitazone over the previous 6 months. Results. The seven transplant patients who had been started on troglitazone therapy experienced a statistically and clinically significant decrease in CsA 12-hr trough levels immediately after the institution of troglitazone therapy. Conclusions. A potential interaction exists between troglitazone and CsA. Transplant patients on CsA who receive troglitazone therapy should be monitored closely.

    Original languageEnglish (US)
    Pages (from-to)1399-1400
    Number of pages2
    Issue number10
    StatePublished - May 27 1998

    ASJC Scopus subject areas

    • Transplantation


    Dive into the research topics of 'Potential interaction of troglitazone and cyclosporine'. Together they form a unique fingerprint.

    Cite this